Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 465   Home Print this page  Email this page Small font size Default font size Increase font size
CASE REPORT
Year : 2018  |  Volume : 10  |  Issue : 3  |  Page : 342-344

Collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder


1 Section of Urology, Medical College of Georgia – Augusta University, Augusta, GA, USA
2 Department of Surgery, Medical College of Georgia – Augusta University, Augusta, GA, USA

Correspondence Address:
Dr. Rabbi Madi
1120 15th Street, Suite Ba 8414, Augusta, GA 30912
USA
Login to access the Email id


DOI: 10.4103/UA.UA_97_17

PMID: 30089999

Rights and Permissions

The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%–28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1760    
    Printed33    
    Emailed0    
    PDF Downloaded184    
    Comments [Add]    

Recommend this journal